Abstract
Gliomas belong to a heterogeneous group of brain tumors with distinct biological and clinical properties that include molecular complexity, as well as inconsistencies in histopathological classification, resulting in an inaccurate prediction of disease progression and failure to use standard therapy. A challenge for the treatment of gliomas is the high recurrence rates. Despite the great …